Keros Therapeutics, Inc. - common stock (KROS)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 70% below Graham Number ($37.73) — significant margin of safety
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 30.4% with 35.6% net margin
- Revenue growing at 2,251% annually
Keros Therapeutics, Inc. - common stock (KROS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $223 million . Key value metrics: P/E ratio 2.6, P/B ratio 0.78, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Keros Therapeutics, Inc. - common stock — Fundamental Analysis Summary
Keros Therapeutics, Inc. - common stock (KROS) is trading 70% below its Graham Number of $37.73 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.6x.
On financial health, KROS shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 30.4% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.12.
StockPik's composite Value Score for KROS is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KROS shows revenue growing at 2,251% year-over-year, with earnings growing at 146%.